Table 2.
Clinical characteristics
| Sham (N = 81) | Active (N = 82) | Total (N = 163) | P-value | |
|---|---|---|---|---|
| Surgery (count (%)) | ||||
| Mastectomy | 25 (31.25%) | 29 (35.80%) | 54 (33.54%) | 0.28* |
| Minimal surgery | 29 (36.25%) | 20 (24.69%) | 49 (30.43%) | |
| Other | 26 (32.50%) | 32 (39.51%) | 58 (36.02%) | |
| Histology (count (%)) | ||||
| IDC | 76 (93.83%) | 68 (82.93%) | 144 (88.34%) | 0.03** |
| Other | 5 (6.17%) | 14 (17.07%) | 19 (11.66%) | |
| Grade (count (%)) | ||||
| 1 | 5 (6.17%) | 6 (7.32%) | 11 (6.75%) | 0.95* |
| 2 | 32 (39.51%) | 33 (40.24%) | 65 (39.88%) | |
| 3 | 44 (54.32%) | 43 (52.44%) | 87 (53.37%) | |
| Stage (count (%)) | ||||
| I | 21 (25.93%) | 16 (19.51%) | 37 (22.70%) | 0.25* |
| IIA | 31 (38.27%) | 27 (32.93%) | 58 (35.58%) | |
| IIB | 15 (18.52%) | 27 (32.93%) | 42 (25.77%) | |
| IIIA | 13 (16.05%) | 12 (14.63%) | 25 (15.34%) | |
| IIIB | 1 (1.23%) | 0 (0.00%) | 1 (0.61%) | |
| Chemotherapy (count (%)) | ||||
| AC | 4 (4.94%) | 7 (8.75%) | 11 (6.83%) | 0.49* |
| AC followed by Taxane | 35 (43.21%) | 29 (36.25%) | 64 (39.75%) | |
| CMF | 1 (1.23%) | 0 (0.00%) | 1 (0.62%) | |
| TC | 31 (38.27%) | 37 (46.25%) | 68 (42.24%) | |
| Other | 10 (12.35%) | 7 (8.75%) | 17 (10.56%) | |
| Neoadjuvant | ||||
| Yes | 26 (32.00%) | 23 (28.00%) | 49 (30.10%) | 0.50** |
| No | 55 (68.00%) | 59 (72.00%) | 114 (69.90%) | |
| Duration of chemotherapy (weeks) | 15.93 ± 5.37 | 16.47 ± 5.42 | 16.20 ± 5.39 | 0.54* |
| Lymphnodes (count (%)) | ||||
| Yes | 35 (44.30%) | 44 (53.66%) | 79 (49.07%) | 0.24** |
| No | 44 (55.70%) | 38 (46.34%) | 82 (50.93%) | |
| Hormonal therapy (count (%)) | ||||
| Yes | 40 (51.95%) | 48 (59.26%) | 88 (55.70%) | 0.36** |
| No | 37 (48.05%) | 33 (40.74%) | 70 (44.30%) | |
| Estrogen receptor (count (%)) | ||||
| Yes | 42 (51.85%) | 48 (58.54%) | 90 (55.21%) | 0.39** |
| No | 39 (48.15%) | 34 (41.46%) | 73 (44.79%) | |
| HER2 NeuExpression (count (%)) | ||||
| Yes | 15 (18.52%) | 24 (29.27%) | 39 (23.93%) | 0.11** |
| No | 66 (81.48%) | 58 (70.73%) | 124 (76.07%) | |
| Progesterone receptor (count (%)) | ||||
| Yes | 34 (41.98%) | 33 (40.24%) | 67 (41.10%) | 0.82** |
| No | 47 (58.02%) | 49 (59.76%) | 96 (58.90%) | |
| LongActingOpiods (count (%)) | ||||
| Yes | 16 (19.75%) | 19 (23.17%) | 35 (21.47%) | 0.60** |
| No | 65 (80.25%) | 63 (76.83%) | 128 (78.53%) | |
| NonSteroidal analgesics (count (%)) | ||||
| Yes | 20 (24.69%) | 10 (12.20%) | 30 (18.40%) | 0.04** |
| No | 61 (75.31%) | 72 (87.80%) | 133 (81.60%) | |
| Anxiolytic (count (%)) | ||||
| Yes | 24 (29.63%) | 17 (20.73%) | 41 (25.15%) | 0.19** |
| No | 57 (70.37%) | 65 (79.27%) | 122 (74.85%) | |
* t-test.
** Chi-square test.